Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Prostatic Neoplasms 3Pancreatic Neoplasms 3Hemangioma 3Urinary Bladder Neoplasms 2Sarcoma, Kaposi 2Sarcoma 2Multiple Myeloma 2Melanoma 2Hemangiosarcoma 2Hemangioma, Cavernous, Central Nervous System 2Breast Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Digestive System Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Propranolol 2DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hemangioma, Cavernous, Central Nervous System × Propranolol × Clear all
NCT03474614 2024-04-19

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

St. Joseph's Hospital and Medical Center, Phoenix

Phase 2 Terminated
4 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

NCT03589014 2022-02-25

Treat_CCM

Mario Negri Institute for Pharmacological Research

Phase 2 Completed
71 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡